论文部分内容阅读
[目的]比较盐酸伊托必利与安慰剂治疗慢性胃炎合并消化不良症状的临床疗效。[方法]120例患者随机分为观察组和对照组各60例,2组均给予对症支持治疗,观察组给予盐酸伊托必利片50 mg饭前口服,每天3次;对照组给予伊托必利模拟片,2周后比较治疗前后的消化不良症状评分、胃排空率和不良反应。[结果]观察组治疗总有效率为93.3%,显著高于对照组的73.3%(P<0.05);治疗后2组的症状总积分均显著下降,观察组的总积分显著低于对照组(P<0.05);治疗前2组胃排空率无明显差别,治疗后观察组胃排空率明显优于对照组(P<0.05);2组患者治疗过程中的不良反应发生率无明显差别。[结论]伊托必利比安慰剂治疗慢性胃炎合并消化不良症状具有良好的效果,能减轻患者总体症状,促进胃排空,不良反应发生率较低,具有广阔应用前景,但其对于上腹不适疗效较差,可能与其增加餐后胃容受性有关。
[Objective] To compare the clinical efficacy of itopride and placebo in the treatment of chronic gastritis complicated with dyspepsia. [Methods] One hundred and twenty patients were randomly divided into observation group and control group, with 60 cases in each group. Both groups were given symptomatic and supportive treatment. In the observation group, 50 mg of itoprimary hydrochloride tablets were orally administered orally 3 times a day before meals. After 2 weeks, we compared the scores of dyspepsia, gastric emptying rate and adverse reactions before and after treatment. [Results] The total effective rate of the observation group was 93.3%, significantly higher than that of the control group (73.3%, P <0.05). After treatment, the total score of the two groups significantly decreased, the total score of the observation group was significantly lower than that of the control group P <0.05). There was no significant difference in gastric emptying rate between the two groups before treatment, after treatment, the gastric emptying rate in the observation group was significantly better than that in the control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups . [Conclusion] Itopilide has better effect than placebo in treating chronic gastritis complicated with dyspepsia symptoms, alleviating the general symptoms and promoting gastric emptying, the incidence of adverse reactions is low, and has broad application prospects. However, Discomfort less effective, may be related to its increased postprandial stomach tolerance.